secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001854270-23-000119
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio partners with Celest for SENTI-301A development in China; up to $156M milestones
--------------------------------------------------------------------------------

- Celest to lead clinical development and manufacturing of SENTI-301A in mainland China; first patient expected 1H 2024.
- Senti Bio retains all commercialization rights outside mainland China, Hong Kong, Macau, and Taiwan.
- Senti eligible for up to $156M in milestone payments plus tiered royalties on potential sales.
- SENTI-301A is an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing hepatocellular carcinoma.
- Pilot trial will enroll 9 patients across two dose cohorts to assess safety and efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/0001854270-23-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/snti-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001854270-23-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer